Skip to main content
SpringerLink
Log in

Peginterferon-α and ribavirin have been recommended for the treatment of mild chronic hepatitis C,

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. National Institute for Health and Clinical Excellence.Thousands more people with hepatitis C to benefit from latest NICE guidance on drug treatments. Media Release: 23 Aug 2006. Available from: URL: http://ww.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peginterferon-α and ribavirin have been recommended for the treatment of mild chronic hepatitis C,. Pharmacoecon. Outcomes News 511, 2 (2006). https://doi.org/10.2165/00151234-200605110-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200605110-00004

Keywords

Search

Navigation